AI Banking Pharma Research Solutions

Is Artificial Intelligence the Next Big Thing in Biotech?

Is Artificial Intelligence the Next Big Thing in Biotech?

Artificial intelligence can drastically reduce the time taken to develop new life-saving drugs. The healthcare industry is not immune to software and technological advancements. In fact, the use of emerging technologies like artificial intelligence () has gradually begun to revolutionize research activities in the industry. Major advances in science and technology are also likely to improve diagnosis and treatment in the future.

copyright by finance.yahoo.com

SwissCognitiveFor example, last year, Glaxo GSK collaborated with two external companies —Exscientia, a UK specialist in machine- and Insilico Medicine, a U.S. leader in -led drug discovery —to harness the power of . Glaxo also has a partnership with driven drug design and development company, Pharmaceuticals. The partnership aims to use for the discovery of novel small-molecule drugs. Sanofi SNY also has a deal with Exscientia to find small molecule drugs for metabolic diseases such as diabetes.

and the Drug Industry

The pharma/biotech industry has started adopting artificial intelligence, the simulation of human intelligence processes by machines, especially computer systems, albeit slowly. It is touted as the next big emerging technology in the biotech industry as it can drastically reduce time and costs involved in developing life-saving drugs.

A significant amount of time is invested in identifying a potential disease target and testing whether a candidate can hit that target. With the use of , it is estimated that the drug design timeframe can be cut down from four to five years to one year, thereby resulting in drastic reduction in costs. Drug/biotech companies can analyze huge amount of data by applying artificial intelligence and machine to identify patterns in ways that humans cannot. Artificial intelligence driven solutions can enable pharma/biotech companies to identify the appropriate patient population, reduce or eliminate the need for some studies, and in some cases even predict outcomes in a virtual patient.

Several collaborations have been formed in the past couple of years between big pharma/biotech players and small -driven companies, primarily startups to discover novel biological targets and molecules for pharma players using .

For example, last year, Glaxo GSK collaborated with two external companies —Exscientia, a UK specialist in machine- and Insilico Medicine, a U.S. leader in -led drug discovery —to harness the power of . Glaxo also has a partnership with driven drug design and development company, Pharmaceuticals. The partnership aims to use for the discovery of novel small-molecule drugs. Sanofi SNY also has a deal with Exscientia to find small molecule drugs for metabolic diseases such as diabetes.

Also, last year, Roche’s RHHBY pharma arm, Genentech formed a research partnership with GNS Healthcare to power cancer drug development with the latter’s REFS causal machine and simulation platform. Amgen and Celgene have also invested in GNS Healthcare. […]

read more – copyright by finance.yahoo.com

 

  1. John Paul Cater

    @SwissCognitive How far are we truly away from sentience? Until then AI is just a buzz phrase. Neural N… https://t.co/waO1jzy4MW

  2. John Paul Cater

    @SwissCognitive When you finally couple AI with synthetic DNA sequencing let me know. I want to see the… https://t.co/RyAkTctU0Q

  3. Amen Andrew-Amen

    @SwissCognitive Applied AI in Biotech’d reshaped pharmaceutical products leading to “dual human syndrome”.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.